ACP 271
Alternative Names: ACP-271Latest Information Update: 31 Mar 2025
At a glance
- Originator ACADIA Pharmaceuticals
- Class
- Mechanism of Action GPR88 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders
Most Recent Events
- 26 Feb 2025 Preclinical trials in Neurological disorders in USA (unspecified route) before February 2025 (ACADIA Pharmaceutical pipeline, February 2025)